Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Capital Expenditures (2016 - 2025)

Avanos Medical's Capital Expenditures history spans 11 years, with the latest figure at $4.8 million for Q4 2024.

  • For Q4 2024, Capital Expenditures fell 18.64% year-over-year to $4.8 million; the TTM value through Dec 2024 reached $17.8 million, changed 0.0%, while the annual FY2025 figure was $31.6 million, 77.53% up from the prior year.
  • Capital Expenditures for Q4 2024 was $4.8 million at Avanos Medical, up from $3.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.9 million in Q2 2020 and bottomed at $3.0 million in Q3 2020.
  • The 5-year median for Capital Expenditures is $4.8 million (2021), against an average of $4.8 million.
  • The largest YoY upside for Capital Expenditures was 116.29% in 2020 against a maximum downside of 69.87% in 2020.
  • A 5-year view of Capital Expenditures shows it stood at $5.1 million in 2020, then decreased by 7.84% to $4.7 million in 2021, then increased by 4.26% to $4.9 million in 2022, then grew by 20.41% to $5.9 million in 2023, then dropped by 18.64% to $4.8 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Capital Expenditures are $4.8 million (Q4 2024), $3.0 million (Q3 2024), and $5.9 million (Q2 2024).